Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aileron Therapeutics, Inc. - Common Stock (NQ:ALRN)

2.110 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aileron Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to enhance lung function in IPF patients. 
Via Benzinga
ALRN Stock Earnings: Aileron Therapeutics Misses EPS for Q2 2024
ALRN stock results show that Aileron Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024
Aileron Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
From Aileron Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Aileron Therapeutics Inc. (NASDAQ: ALRN) Closes Underwritten Registered Direct Offering
Via Investor Brand Network
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering 
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering 
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
From Aileron Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Aileron Therapeutics Inc. (NASDAQ: ALRN) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023
Aileron Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics Announces CEO Transition
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis 
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Getaround Shares Are Trading Higher By Around 86%; Here Are 20 Stocks Moving Premarket
Shares of Getaround, Inc. (NYSE: GETR) rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to dive into the biggest pre-market stock movers for Friday morning as we check out the winners and losers today! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Top 5 Health Care Stocks That May Collapse In Q2
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.